Special Drug Use-results Surveillance of Scemblix Tablets (Resistant or Intolerant Chronic Myeloid Leukemia , CABL001A1401)
Special Drug Use-results Surveillance of Scemblix Tablets (Resistant or Intolerant Chronic Myeloid Leukemia , CABL001A1401)
Uncontrolled, central registration system, all-case, multicenter, special drug use-results surveillance.
The objective of this study is to collect data on the occurrence, severity, clinical courses of the safety specifications of asciminib, identify factors etc. involved in occurrence and assess its clinical safety inresistant/intolerant chronic myelogenous leukemia patients during an observational period of 48 weeks from the start of treatment with asciminib.
Inclusion Criteria:
Exclusion Criteria:
NA
Yoshida-gun, Fukui 910-1193, Japan
Kakogawa-shi, Hyōgo 675-8611, Japan
Higashiibaraki-gun, Ibaraki 311-3193, Japan
Shiwa-gun, Iwate 028-3695, Japan
Kita-gun, Kagawa-ken 761-0793, Japan
Shimajiri-Gun, Okinawa 901-1303, Japan
Iruma-gun, Saitama 350-0495, Japan
Sunto Gun, Shizuoka 411 8777, Japan
Bunkyo Ku, Tokyo 113-8431, Japan
Bunkyo Ku, Tokyo 113-8677, Japan
Bunkyo-ku, Tokyo 113-8603, Japan
Chiyoda-ku, Tokyo 101-8643, Japan
Chiyoda-ku, Tokyo 102-8798, Japan
Itabashi Ku, Tokyo 173 0015, Japan
Itabashi Ku, Tokyo 173 8606, Japan
Koto Ku, Tokyo 135 8550, Japan
Meguro-ku, Tokyo 152-8902, Japan
Minato Ku, Tokyo 105-8470, Japan
Minato-ku, Tokyo 105-8471, Japan
Minato-ku, Tokyo 108-8639, Japan
Nerima-ku, Tokyo 113-0033, Japan
Shinagawa Ku, Tokyo 141 8625, Japan
Shinagawa-ku, Tokyo 142-8666, Japan
Shinjuku Ku, Tokyo 162 8655, Japan
Shinjuku Ku, Tokyo 162 8666, Japan
Shinjuku-ku, Tokyo 160 8582, Japan
Shinjuku-ku, Tokyo 160-0023, Japan
Suginami, Tokyo 166-0001, Japan
Sumida-ku, Tokyo 130-8575, Japan